GlucoFriend-evaluation the Effectiveness of Glucobay When Combined With a Basal Insulin
Information source: Bayer
Information obtained from ClinicalTrials.gov on December 08, 2011
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Diabetes Mellitus
Intervention: Acarbose (Glucobay, BAYG5421) (Drug)
Phase: N/A
Status: Recruiting
Sponsored by: Bayer Official(s) and/or principal investigator(s):
Bayer Study Director, Study Director, Affiliation: Bayer
Overall contact:
Bayer Clinical Trials Contact, Email: clinical-trials-contact@bayerhealthcare.com
Summary
To evaluate the effectiveness of Glucobay when combined with a basal insulin under
daily-life treatment conditions in a large sample of Korean patients.
Clinical Details
Official title: Combined Use of a Basal Insulin and Glucobay For Reducing PPG to End Diabetes Progress
Study design: Time Perspective: Prospective
Primary outcome: Postprandial Blood Glucose
Secondary outcome: Duration and dose of acarbose treatmentChange in HbA1c
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Signed written informed consent
- Age ≥ 18 years
- Diagnosed of type 2 diabetes for at least 6 months prior to enrollment
- Patients treated with stable dose of a basal insulin (insulin glargine or insulin
detemir) at least 2 months
- HbA1C≥7. 5 and ≤10. 0%
Exclusion Criteria:
- Exclusion criteria must be read in conjunction with the local product information
Locations and Contacts
Bayer Clinical Trials Contact, Email: clinical-trials-contact@bayerhealthcare.com
Many Locations, Korea, Republic of; Recruiting
Additional Information
Click here and search for drug information provided by the FDA. Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product. Click here to find results for studies related to marketed products.
Starting date: November 2010
Last updated: November 18, 2011
|
